Session » Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session III

Date: Tuesday, November 10, 2015

Time: 9:00AM-11:00AM

Meeting: 2015 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 2957

25-Hydroxyvitamin D3 Deficiency Independently Predicts Cognitive Impairment in Patients with Systemic Lupus Erythematosus: Results from a Controlled Study

9:00AM-11:00AM: Abstract Number: 2932

A Retrospective Observational Study of Patients with Lupus Nephritis Treated with Rituximab in Combination with Cyclophosphamide

9:00AM-11:00AM: Abstract Number: 2909

A Systematic Review and Meta-Analysis of Cutaneous Manifestations in Late Versus Early-Onset Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2916

Analysis of Risk Factors of the Progression to Chronic Kidney Disease and Comorbidities in Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 2901

Anti-dsDNA Antibodies Measured By Chemiluminescent Immunoassay Show Strong Association with Active Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 2951

Anti-NR2 Antibody and Blood-Brain Barrier Disruption in Systemic Lupus Erythematosus Patients with Cognitive Dysfunction

9:00AM-11:00AM: Abstract Number: 2947

Association of Anti-NR2 and U1RNP Antibodies with Neurotoxic Inflammatory Mediators in Cerebrospinal Fluid from Patients with Neuropsychiatric Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2938

Baseline Predictors of Remission and Low Disease Activity Using Recently Defined International Criteria in a Multi-Center Lupus Registry Cohort

9:00AM-11:00AM: Abstract Number: 2906

Can Immunosuppressive Drug Treatment Reduce Mortality in Patients with Systemic Lupus Erythematosus (SLE): A Propensity Score Analysis of a Longitudinal Cohort of 803 Patients?

9:00AM-11:00AM: Abstract Number: 2955

Cognitive Impairment in Lupus Patients: Identification of the Best Screening Test and Assessment for Associated Factors

9:00AM-11:00AM: Abstract Number: 2917

Combined Proliferative and Membranous Lupus Nephritis: Is the Prognosis Really Poor?

9:00AM-11:00AM: Abstract Number: 2912

Concomitant Kidney Disease in Patients with Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 2926

Cytochrome P450 Polymorphisms on Blood Hydroxychloroquine Levels in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2924

Determinants of Damage in an SLE Cohort: Real World Data

9:00AM-11:00AM: Abstract Number: 2952

Diagnosis of Primary Neuropsychiatric Systemic Lupus Erythematosus: Attribution Models Versus Physician Judgment

9:00AM-11:00AM: Abstract Number: 2908

Diagnostic and Screening Accuracy of Spot Urinary Protein-Creatinine Ratio Compared to Protein Content in a 24 Hour-Urine Collection in Systemic Lupus Erythematosus: Systematic Review and Meta-Analysis

9:00AM-11:00AM: Abstract Number: 2929

Diet and Glucocorticoid Treatment in Patients with SLE

9:00AM-11:00AM: Abstract Number: 2949

Differential Serum Cytokine Profile in Patients with Systemic Lupus Erythematosus and Posterior Reversible Encephalopathy Syndrome: A Single-Center Study

9:00AM-11:00AM: Abstract Number: 2945

Diffuse Alveolar Hemorrhage in SLE: Risk Factors, Response to Therapy, and Survival

9:00AM-11:00AM: Abstract Number: 2927

Disease Activity Patterns over Time in Patients with SLE – a Retrospective Descriptive Analysis of the Hopkins Lupus Cohort

9:00AM-11:00AM: Abstract Number: 2935

Disease Evolution in Late Onset and Early Onset Systemic Lupus Erythematosus (SLE)

9:00AM-11:00AM: Abstract Number: 2918

Do Patients with Lupus Nephritis Who Achieve Complete Proteinuria Recovery at 2 Years Have Better Long Term Outcomes Compared to Patients with Partial Proteinuria Recovery?

9:00AM-11:00AM: Abstract Number: 2919

Effect of Thrombotic Microangiopathy on Clinical Outcomes in LUPUS Nephritis

9:00AM-11:00AM: Abstract Number: 2934

Endothelial Dysfunction in SLE-the Role of Platelets and Type I Interferon

9:00AM-11:00AM: Abstract Number: 2898

Erythrocytes, Acanthocytes, and Proteins in Urine Reflect Lupus Nephritis Histology

9:00AM-11:00AM: Abstract Number: 2936

Evolution of Disease Burden over 7 Years in a Multicentre Inception SLE Cohort

9:00AM-11:00AM: Abstract Number: 2925

Factors Associated with Early Damage Accrual in Patients with Systemic Lupus Erythematosus: 12-Month Preliminary Results from the Inception Cohort of the Multicenter Early Lupus Project

9:00AM-11:00AM: Abstract Number: 2922

HLA-Specific Antibody Profile in Renal Transplant Patients with Systemic LUPUS Erythematosus

9:00AM-11:00AM: Abstract Number: 2910

How Accurate Is Spot Urine Protein/Creatinine Ratio in Measuring the Change over Time in Proteinuria Level Compared to the 24 Hour Proteinuria Test?

9:00AM-11:00AM: Abstract Number: 2948

How Do Patients with Newly Diagnosed SLE Present? a Multicenter Cohort Analysis to Inform the Development of New Classification Criteria for SLE

9:00AM-11:00AM: Abstract Number: 2913

Intensified Treatment of B Lymphocyte Depletion (ITBLD) without Immunosuppressive Maintenance Treatment As a Rescue Therapy in Refractory Lupus Nephritis (LN): A 4-Year Observation

9:00AM-11:00AM: Abstract Number: 2931

Is Pregnancy a Risk Factor for the Onset of Systemic Lupus Erythematosus (SLE) in Women of the Reproductive Age: A Population Based Case-Control Study?

9:00AM-11:00AM: Abstract Number: 2903

Late-Onset Neutropenia Following Rituximab Treatment in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2942

Longitudinal Analyses of Progression of Brain Athrophy in Childhood-Onset Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2933

Low Prevalence of PCP in Hospitalized Patients with SLE: Review of a Clinical Database Warehouse

9:00AM-11:00AM: Abstract Number: 2921

Lupus Nephritis: An Exploration of Management Style

9:00AM-11:00AM: Abstract Number: 2914

Modifiable and Non-Modifiable Correlates of Satisfaction with Care in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2946

Mortality Among SLE Patients in the National Data Bank for Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 2899

Mortality Related to Pediatric Systemic Lupus Erythematosus: A Multiple Cause-of-Death Analysis in France

9:00AM-11:00AM: Abstract Number: 2930

Outcome of Patients with Systemic Lupus Erythematous (SLE) after Thrombotic Events

9:00AM-11:00AM: Abstract Number: 2941

Outcomes in Lupus Nephritis Patients Previously Randomized to Receive Either Low Dose Cyclophosphamide Versus Oral Mycophenolate Mofetil on Azathioprine Maintenance

9:00AM-11:00AM: Abstract Number: 2956

Patients’ Reported Perceived Deficits Questionnaire – 5-Item Is Not Valid to Screen for Cognitive Impairment in Lupus

9:00AM-11:00AM: Abstract Number: 2959

Patterns of Vascular Brain Injury in Systemic Lupus Erythematosus Patients with Ischemic Stroke: Impact on Neuropsychological, Neurobehavioral and Physical Function Outcome

9:00AM-11:00AM: Abstract Number: 2928

Persistent Disease Activity over Time in a Large Canadian Cohort of Prevalent Lupus Patients

9:00AM-11:00AM: Abstract Number: 2900

Phospholipase A2 Receptor 1 Antibody in Membranous Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 2897

Predictors of Organ Damage Progression and Impact on Health-Related Quality of Life in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2943

Preliminary Population-Based Incidence and Prevalence Estimates of Systemic Lupus Erythematous from the Manhattan Lupus Surveillance Program

9:00AM-11:00AM: Abstract Number: 2944

Presepsin (sCD14 subtype) Concentration Is Elevated and Reflects Disease Activity in Systemic Lupus Erythematous Patients

9:00AM-11:00AM: Abstract Number: 2940

Risk Factors for Late-Onset Thrombosis in Systemic Lupus Erythematosus (SLE)

9:00AM-11:00AM: Abstract Number: 2954

Serum and CSF Biomarkers of Neuropsychiatric Involvement in Primary Sjogren Syndrome and Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2923

The Effects of Disease Activity and Mood Disorders on Cognitive Function in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2953

The Emergency Room and SLE: What Characteristics Are Associated with Increased Emergency Room Utilization in Lupus Patients?

9:00AM-11:00AM: Abstract Number: 2939

The Impact of Tabalumab on the Kidney in Systemic Lupus Erythematosus: Results from Two Phase 3 Randomized Clinical Trials

9:00AM-11:00AM: Abstract Number: 2902

The Initial Presentation of Cerebrovascular Disease Attributed to Lupus Is Most Frequent Early in the Disease Course: Results from an International, Inception Cohort Study

9:00AM-11:00AM: Abstract Number: 2907

The Natural History of Thrombotic Events in Systemic Lupus Erythematosus and Associated Risk Factors

9:00AM-11:00AM: Abstract Number: 2915

The Utility of Lupus Serology in Predicting Outcomes of Renal Transplantation in Lupus Patients: Systematic Review and Analysis of a Large Lupus Cohort

9:00AM-11:00AM: Abstract Number: 2920

Time to Recovery of Individual Lupus Manifestations on Standard of Care Treatment

9:00AM-11:00AM: Abstract Number: 2937

Treatment Patterns Differ Based on Age of Systemic Lupus Erythematosus Onset: A Comparison of Azathioprine and Mycophenolate on the Prevention of Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 2911

Tubulointerstitial Involvement in Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 2905

Urinary Protein:Urinary Creatinine Ratio in an Untimed Urine Specimen and Estimated Glomerular Filtration Rate Are Reliable Measures of Proteinuria and Renal Function in Patients with Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 2950

Using Electronic Health Record Algorithms to Accurately Identify Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2904

Utility of Untimed Single Urine Protein/Creatinine Ratio As a Substitute for the 24 Hour Proteinuria for the Assessment of Proteinuria in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2958

Vitamin D, Cognition and Cerebral Structural Abnormalities in Childhood- Onset Systemic Lupus Erythematosus

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].